# A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) in Combination With COPEGUS (Ribavirin) in Interferon-Naive Patients With Chronic Hepatitis C Infection (CHC).

> **NCT00077649** · PHASE4 · COMPLETED · sponsor: **Hoffmann-La Roche** · enrollment: 188 (actual)

## Conditions studied

- Hepatitis C, Chronic

## Interventions

- **DRUG:** ribavirin [Copegus]
- **DRUG:** ribavirin [Copegus]
- **DRUG:** peginterferon alfa-2a (PEG-IFN alfa-2a) [Pegasys]
- **DRUG:** peginterferon alfa-2a (PEG-IFN alfa-2a) [Pegasys]

## Key facts

- **NCT ID:** NCT00077649
- **Lead sponsor:** Hoffmann-La Roche
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-01
- **Primary completion:** 2005-12
- **Final completion:** 2005-12
- **Target enrollment:** 188 (ACTUAL)
- **Last updated:** 2016-04-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00077649

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00077649, "A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) in Combination With COPEGUS (Ribavirin) in Interferon-Naive Patients With Chronic Hepatitis C Infection (CHC).". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT00077649. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*